Coherus Biosciences Inc (CHRS)

08:42 AM

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2025 Earnings Call Transcript - Insider Monkey

08:42 AM

05:27 AM

Coherus BioSciences Q1 2025 Earnings Call Transcript - MarketBeat

05:27 AM

03:10 AM

Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance

03:10 AM

12:05 PM

Coherus BioSciences: Q1 2025 Financial Highlights and Strategic Shift - TipRanks

12:05 PM

May 12, 2025

Coherus BioSciences (CHRS) Focuses on Oncology After Divestitures - GuruFocus

May 12, 2025

May 12, 2025

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 12, 2025

May 12, 2025

Earnings call transcript: Coherus BioSciences sees flat revenue, stock slides post-Q1 2025 - Investing.com UK

May 12, 2025

May 12, 2025

Coherus BioSciences Inc Reports Q1 2025 Results: EPS of $(0.41) Misses Estimate, Revenue at $7.6 Million Falls Short - GuruFocus

May 12, 2025

May 12, 2025

Coherus BioSciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025

May 12, 2025

Coherus BioSciences (CHRS) Reports Q1 Revenue Surge, Faces Share Decline - GuruFocus

May 12, 2025

May 12, 2025

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

May 12, 2025

May 12, 2025

Coherus BioSciences: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025

May 12, 2025

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | CHRS Stock News - GuruFocus

May 12, 2025

May 12, 2025

Coherus BioSciences Reports Q1 2025 Financial Results and Advances Oncology Portfolio with CHS-114 and LOQTORZI Developments - Nasdaq

May 12, 2025

May 10, 2025

COHERUS BIOSCIENCES Earnings Preview: Recent $CHRS Insider Trading, Hedge Fund Activity, and More - Nasdaq

May 10, 2025

May 10, 2025

Coherus BioSciences (CHRS) Q1 Earnings Preview: Declining Revenue Expected - GuruFocus

May 10, 2025

May 09, 2025

Coherus BioSciences Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView

May 09, 2025

May 09, 2025

What To Expect From Coherus BioSciences Inc (CHRS) Q1 2025 Earnings - GuruFocus

May 09, 2025

May 08, 2025

Coherus at The Citizens JMP Life Sciences: Strategic Oncology Focus By Investing.com - Investing.com Australia

May 08, 2025

May 08, 2025

Coherus at The Citizens JMP Life Sciences: Strategic Oncology Focus - Investing.com

May 08, 2025

May 05, 2025

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - GlobeNewswire

May 05, 2025

May 05, 2025

Coherus To Report First Quarter 2025 Financial Results On May 12, 2025 - Barchart.com

May 05, 2025

May 05, 2025

Coherus Sets Q1 2025 Earnings Date: How to Join the May 12 Conference Call - Stock Titan

May 05, 2025

May 01, 2025

Coherus to Participate in Upcoming Investor Conferences | CHRS S - GuruFocus

May 01, 2025

May 01, 2025

Coherus to Participate in Upcoming Investor Conferences | CHRS Stock News - GuruFocus

May 01, 2025

May 01, 2025

Coherus to Participate in Upcoming Investor Conferences - GlobeNewswire

May 01, 2025

May 01, 2025

Coherus BioSciences Sets Strong Presence at Top Healthcare Conferences: Key Oncology Updates Expected - Stock Titan

May 01, 2025

Apr 29, 2025

Coherus Presents Promising Early Clinical Data from Phase 1 Dose - GuruFocus

Apr 29, 2025

Apr 28, 2025

Coherus BioSciences Phase 1 Trial of CHS-114 Shows Confirmed Partial Response in Cancer Patient - marketscreener.com

Apr 28, 2025

Apr 28, 2025

Coherus reports promising cancer treatment results - Investing.com

Apr 28, 2025

Apr 28, 2025

Coherus (CHRS) Advances Clinical Trial for Anti-CCR8 Antibody in Cancer Treatment | CHRS Stock News - GuruFocus

Apr 28, 2025

Apr 28, 2025

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 - The Manila Times

Apr 28, 2025

Apr 28, 2025

Coherus BioSciences Reports Promising Clinical Data for CHS-114 Combined with Toripalimab in HNSCC and Gastric Cancer - Nasdaq

Apr 28, 2025

Apr 28, 2025

Coherus Presents Promising Early Clinical Data from Phase 1 - GlobeNewswire

Apr 28, 2025

Apr 28, 2025

Breakthrough Cancer Treatment: Coherus Drug Shows Promise in Hard-to-Treat Head and Neck Cancer Patients - Stock Titan

Apr 28, 2025

Apr 26, 2025

Coherus BioSciences, Inc. to Host Earnings Call - ACCESS Newswire

Apr 26, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 23, 2025

1 of Wall Street’s Favorite Stock with Impressive Fundamentals and 2 to Turn Down - The Globe and Mail

Apr 23, 2025

Apr 23, 2025

Coherus BioSciences announces CCO Paul Reider’s resignation By Investing.com - Investing.com India

Apr 23, 2025

Apr 22, 2025

Coherus BioSciences announces CCO Paul Reider’s resignation - Investing.com Australia

Apr 22, 2025

Apr 21, 2025

3 Reasons We Love Chart (GTLS) - The Globe and Mail

Apr 21, 2025

Apr 17, 2025

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs - Seeking Alpha

Apr 17, 2025

Apr 16, 2025

Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment - insights.citeline.com

Apr 16, 2025

Apr 15, 2025

Coherus divests Udenyca franchise to Intas for up to $558.4m - MSN

Apr 15, 2025

Apr 15, 2025

Latham & Watkins Assists Coherus BioSciences in Obtaining CFIUS Clearance - Latham & Watkins LLP

Apr 15, 2025

Apr 15, 2025

Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals

Apr 15, 2025

Apr 15, 2025

Intas acquires Neulasta biosimilar Udenyca from Coherus BioSciences - World Pharmaceutical Frontiers

Apr 15, 2025

Apr 15, 2025

Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals

Apr 15, 2025

Apr 14, 2025

Coherus BioSciences (CHRS) Completes Divestiture of UDENYCA Fran - GuruFocus

Apr 14, 2025

Apr 14, 2025

Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million - marketscreener.com

Apr 14, 2025